As Testosterone Treatment Lawsuits Mount, Bernstein Liebhard LLP Notes Scheduling of FDA Meeting to Address Risks Associated with Low Testosterone Therapy

The Firm is evaluating testosterone lawsuits on behalf of men who allegedly suffered heart attacks, strokes, and other cardiovascular problems due to their use of testosterone replacement medications.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
Our Firm hears regularly from men who allegedly suffered heart attacks, strokes and other cardiovascular problems due to the use of AndroGel and other low testosterone drugs. We are pleased that the FDA is moving forward with its investigation.

New York, NY (PRWEB) July 21, 2014

As testosterone treatment lawsuits (http://www.testosteronelawsuitclaims.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) has scheduled a meeting of outside advisors to discuss the risks associated with prescription low testosterone therapy. According to a notice posted on the agency’s website, the joint meeting of the Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will be convened on September 17, 2014, at which time the members will be asked to make recommendations pertaining to the cardiovascular side effects associated with the medications. The Committees will also address what factors should be considered when deciding whether men need to use low testosterone therapy.*

“Our Firm hears regularly from men who allegedly suffered heart attacks, strokes and other cardiovascular problems due to the use of AndroGel and other low testosterone drugs. We are pleased that the FDA is moving forward with its investigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating testosterone lawsuits on behalf of men who were allegedly harmed by these medications.

Testosterone Lawsuits
Low testosterone therapies are indicated for the treatment of hypogonadism (low testosterone) in men who suffer from the disorder due to an underlying illness or injury. In addition to AndroGel, other drugs in this class include:**

  • Axiron
  • AndroDerm
  • AndroGel
  • Bio-T Gel
  • Delatestryl
  • Depo-Testosterone
  • Foresta
  • Striant
  • Testopel
  • Testim

In January, the FDA announced it was reviewing the heart risks associated with this low testosterone therapy, after two studies indicated that older men, as well as those with pre-existing heart disease, were more likely to suffer heart attacks, strokes or death if they were undergoing low testosterone therapy. The agency’s advisory panel meeting is scheduled to take place from 8:00 a.m. to 5:00 p.m. on September 17th in Hyattsville, Maryland. According to the notice, oral presentations from the public will be scheduled between approximately 1:00 p.m. to 2:00 p.m. on September 17, 2014.*

Since the FDA announced its investigation, court records indicate more than 150 testosterone treatment lawsuits have been filed in U.S. courts on behalf of men who were allegedly harmed by AndroGel and similar drugs. The majority of these claims are pending in a multidistrict litigation now underway in U.S. District Court, Northern District of Illinois. Among other things, the claims similarly allege that the manufacturers of testosterone replacement therapies failed to provide adequate warnings regarding the cardiovascular risks associated with their products. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

Victims of heart attacks, strokes, and other cardiovascular events allegedly associated with low testosterone therapy may be entitled to file their own testosterone treatment lawsuit. To learn more, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*fda.gov/AdvisoryCommittees/Calendar/ucm404905.htm, FDA, July 17, 2014
**accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&searchTerm=testosterone&Search_Button=Submit

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuitclaims.com/
https://plus.google.com/115936073311125306742?rel=author